Using Climate-HIV to describe real-world clinical outcomes for people living with HIV taking dolutegravir-based regimens. (October 2021)

• Record Type: Journal Article
• Authors: Okoli, Chinyere; Schwenk, Achim; Radford, Matthew; Myland, Melissa; Taylor, Stephen; Barnes, Justine; Fox, Ashini; Darley, Alison; Grimson, Fiona; Reeves, Iain; Munshi, Sajid; Croucher, Adam; Boxall, Naomi; Paice, Alistair; van Wyk, Jean; Benn, Paul
• Is Part Of: International journal of STD & AIDS. Volume 32:Number 12(2021)
• Page Start: 1165
• Page End: 1173
• Publication Date: 2021-10
• Subjects: Clinical practice data -- HIV-1 -- dolutegravir -- real-world outcomes -- Climate-HIV; Sexually transmitted diseases -- Periodicals; AIDS (Disease) -- Periodicals; 616.951
• DOI: 10.1177/09564624211027099
• Languages: English
• ISSNs: 0956-4624

Abstract

Objectives: The objective of this study was to describe the real-world use and effectiveness of dolutegravir-based regimens (DBRs) in routine clinical practice in the United Kingdom. Methods: Retrospective analysis was conducted using data from four National Health Service trusts using Climate-HIV, an electronic case record system. Eligible patients were aged ≥18 years with HIV-1 infection who were prescribed a DBR from December 2012 to March 2018. Outcome measurements were accessed at DBR initiation and at weeks 24, 48 and 96 and the last recorded visit up to the extraction date (last measurement). The primary endpoint was the proportion of patients with HIV-1 RNA <50 copies/mL at Week 48. Results: The study cohort included 934 patients; 337 (36%) were female, 414 (47%) were white and 717 (77%) were treatment experienced (TE). The Kaplan–Meier estimated probability of achieving HIV-1 RNA <50 copies/mL at 48 weeks was 96% for treatment-naive (TN) patients and 86% for TE patients. Median times to viral suppression (<50 copies/mL) were 49 and 57 days for TN and TE patients with detectable baseline viral load, respectively, according to Kaplan–Meier analysis. Median follow-up time was 377 days (interquartile range: 131–683). At last measurement, 87% (809/934) of patients remained on a DBR; among those patients, 681 (84%) had HIV-1 RNA <50 copies/mL. Conclusions: High levels of virologic suppression and low rates of discontinuation of DBRs were seen in a large, diverse, UK-based population with HIV-1 infection. These findings are broadly consistent with efficacy data from phase III studies.